Search
Esophageal / GE Junction
A232402CD
PAGODA: RANDOMIZED TRIAL OF A PROACTIVE GRADUATED DOSE MODIFICATION ALGORITHM FOR FOLFOX CHEMOTHERAPY TO PREVENT UNPLANNED DELAYS
EAQ222CD
Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
A022102 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA
EAY191-N5 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors. A ComboMATCH Treatment Trial
S2303 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**
Molecular Analysis for Combination Therapy Choice
ALLIANCE A212102 **AT MBMC ONLY** ***Participant Engagement Portal (PEP) is Closed to New Patient Registration as of 9/15/25*** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**
Blinded Reference Set For Multicancer Early Detection Blood Tests
